
STERIS (STE) Stock Forecast & Price Target
STERIS (STE) Analyst Ratings
Bulls say
Steris, a global leader in sterilization services and infection prevention, reported a 6.5% organic revenue growth in its healthcare segment, indicating strong demand for its services. The company has updated its fiscal year 2025 revenue guidance to reflect a forecast of 6% organic growth, supported by a notable 9.5% growth in its Applied Sterilization Technologies segment. Despite facing foreign exchange headwinds, Steris remains well-positioned to capitalize on increased healthcare utilization and capital spending in hospitals and life sciences.
Bears say
Steris experienced a slight revenue miss in its 3Q25 results, primarily driven by a 17% year-over-year decline in service revenues and a noteworthy 15% decrease in Capital Equipment sales, indicating potential weaknesses in key business segments. The company's guidance has been adjusted downward, anticipating further challenges in healthcare capital equipment revenues, which are projected to decrease in the coming quarter. Additionally, the resurgence of COVID-19 is expected to adversely impact procedural volumes, further restricting demand for Steris's products and services, compounding integration and geographic risks associated with its acquisitions.
This aggregate rating is based on analysts' research of STERIS and is not a guaranteed prediction by Public.com or investment advice.
STERIS (STE) Analyst Forecast & Price Prediction
Start investing in STERIS (STE)
Order type
Buy in
Order amount
Est. shares
0 shares